NeuroVive Pharmaceutical ABの発行済株式数
NeuroVive Pharmaceutical ABの発行済株式数は何ですか。
NeuroVive Pharmaceutical ABの発行済株式数は49.459Mです。
発行済株式数の定義は何ですか。
発行済株式数は、投資家によって承認、発行、購入され、保有されている法人または金融資産のすべての株式である。
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
LSEのセクタMiscellaneousにおける発行済株式数の企業と比べるNeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical ABは何をしますか。
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
NeuroVive Pharmaceutical ABと類似の発行済株式数
- Regenxbio Incの発行済株式数は49.423Mです。
- Oncternal Therapeuticsの発行済株式数は49.427Mです。
- SKF Indiaの発行済株式数は49.438Mです。
- SKF Indiaの発行済株式数は49.438Mです。
- Knoll Incの発行済株式数は49.441Mです。
- California Resources Corpの発行済株式数は49.453Mです。
- NeuroVive Pharmaceutical ABの発行済株式数は49.459Mです。
- Navin Fluorine Internationalの発行済株式数は49.495Mです。
- News Investの発行済株式数は49.545Mです。
- Navin Fluorine Internationalの発行済株式数は49.545Mです。
- DoubleDown Interactive Coの発行済株式数は49.553Mです。
- Prestige Consumer Healthcare Incの発行済株式数は49.557Mです。
- Beauce Gold Fieldsの発行済株式数は49.561Mです。